使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
As a reminder, this call is being recorded. Please proceed.
提醒各位,本次電話會議正在錄音。請繼續。
William Brent Turner - President
William Brent Turner - President
Good morning. I'm Brent Turner, President of Acadia Healthcare, and I'd like to welcome you to our second quarter 2017 conference call.
各位早安。我是 Acadia Healthcare 總裁 Brent Turner,歡迎各位參加我們 2017 年第二季電話會議。
To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link.
若今日電話會議中討論任何非 GAAP 財務衡量指標,您也可透過我們網站的 Investors 連結,查看昨日新聞稿,以取得該指標與依 GAAP 計算之最直接可比財務衡量指標的調節表。
This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2017 and beyond. For this purpose, any statements made during this call that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are hereby cautioned that these statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's second quarter news release. And consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. The company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
本次電話會議可能包含《1995 年私人證券訴訟改革法》所定義的前瞻性陳述,其中包括但不限於關於 Acadia 對 2017 年及其後各季與全年預期財務表現的陳述。就此而言,本次電話會議中任何非歷史事實之陳述,均可能被視為前瞻性陳述。在不限制前述內容的情況下,believes、anticipates、plans、expects 及類似用語旨在識別前瞻性陳述。特此提醒您,這些陳述可能受到多項重要因素影響(其中包括但不限於)Acadia 向美國證券交易委員會提交之文件以及公司第二季新聞稿中所載之因素。因此,實際營運與結果可能與前瞻性陳述中討論之結果存在重大差異。公司不承擔公開更新任何前瞻性陳述之義務,不論係因新資訊、未來事件或其他原因。
At this time, for opening remarks, I'll now turn the call conference over to our Chairman and Chief Executive Officer, Joey Jacobs.
現在進入開場致詞,我將把電話會議交給我們的董事長兼執行長 Joey Jacobs。
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Good morning, everyone, and welcome to our Second Quarter Conference Call. In addition to Brent, I'm here today with our Chief Financial Officer, David Duckworth, and other members of our executive management team. David and I each have some remarks about the second quarter and our outlook for Acadia, then we'll open the line for your questions.
各位早安,歡迎參加我們的第二季電話會議。除了 Brent 之外,今天與我一同出席的還有我們的財務長 David Duckworth,以及其他執行管理團隊成員。David 和我將各自就第二季表現與 Acadia 的展望做一些說明,之後我們將開放提問。
Acadia's second quarter results exceeded our expectations and we were pleased with the improvement in our operations for the quarter. This improvement was especially clear with our stronger performance in same facility revenue on a consolidated basis and in both the U.S. and the U.K. Even though we faced very tough comparisons for the second quarter of last year, in fact, our 6.5% consolidated same facility growth and 7.8% growth for our U.S. operations were our best rate of same facility growth for the last 4 quarters.
Acadia 第二季業績超出我們的預期,我們對本季營運改善感到滿意。這項改善在合併基礎的同院所營收,以及美國與英國兩地更強勁的表現上尤其明顯。儘管我們面臨去年第二季非常艱難的比較基期,事實上,我們合併同院所成長 6.5% 以及美國業務成長 7.8%,是過去 4 個季度以來同院所成長率的最佳表現。
As our outlook indicated, we expected our second quarter results to be better than the first quarter. We were pleased with the results and the sequential improvement from the first quarter, highlighted by: revenue increase of $36.7 million; adjusted EBITDA increase of $25.9 million; margin improvement of 260 basis points; decline in salary, wages and benefits as a percentage of net revenue of 180 basis points from 54.3% to 52.5%; and adjusted EPS increase from $0.46 to $0.66.
如同我們的展望所示,我們預期第二季表現會優於第一季。我們對本季成果及相較第一季的逐季改善感到滿意,重點包括:營收增加 3,670 萬美元;調整後 EBITDA 增加 2,590 萬美元;利潤率提升 260 個基點;薪資、工資與福利占淨營收比重下降 180 個基點,從 54.3% 降至 52.5%;以及調整後 EPS 從 0.46 美元提升至 0.66 美元。
For the second quarter, we added 91 beds, and we remain on pace to open approximately 800 new beds during 2017 in the existing facilities and 3 de novo facilities scheduled to open in the second half of the year.
第二季我們新增 91 張床位,且我們仍按計畫在 2017 年於既有院所及預計於下半年開業的 3 家新設(de novo)院所中,合計新增約 800 張床位。
In the third quarter alone, we anticipate opening more than 250 beds as well as adding beds to our existing facilities. We've also remained very focused at the individual facility level in driving additional revenues, primarily through program enhancements and other growth investments. We are continuing to actively evaluate additional acquisitions, primarily in the U.S., and we are believed that we are well positioned to fund our acquisition strategy.
僅第三季,我們預期將開設超過 250 張床位,並在既有院所增設床位。我們也持續在單一院所層級高度聚焦於推動額外營收,主要透過方案強化與其他成長投資。我們持續積極評估其他併購機會,主要在美國,同時我們相信自身具備良好條件為併購策略提供資金。
Additionally, given our scale, operations expertise and independence, we believe we are an attractive behavioral health joint venture partner for acute care hospitals, as evidenced by our most recent joint venture agreements in Ohio and Pennsylvania. We are very optimistic about all of our potential growth opportunities. We remain excited for the future and confident in our team and business model.
此外,憑藉我們的規模、營運專業與獨立性,我們相信自己是急性照護醫院在行為健康領域合資合作的理想夥伴,這點可由我們近期在俄亥俄州與賓夕法尼亞州的合資協議得到印證。我們對所有潛在成長機會都非常樂觀。我們對未來仍感到振奮,並對我們的團隊與商業模式充滿信心。
Thanks for your time this morning and your interest in Acadia. Now here's David Duckworth to take you through the financials.
感謝各位今早撥冗以及對 Acadia 的關注。接下來請 David Duckworth 帶各位回顧財務表現。
David M. Duckworth - CFO, CAO and Controller
David M. Duckworth - CFO, CAO and Controller
Thanks, Joey, and good morning. The company's revenue for the second quarter of 2017 was $715.9 million, a 5.4% decline from $756.5 million for the second quarter last year. Adjusting for the impact of the divestiture, other discontinued operations and the decline in the exchange rate, the company's revenue increased 6.4% from pro forma revenue of $672.9 million for the second quarter of 2016.
謝謝你,Joey,各位早安。公司 2017 年第二季營收為 7.159 億美元,較去年第二季的 7.565 億美元下降 5.4%。若調整剝離(divestiture)、其他已終止營運以及匯率下滑的影響,公司營收較 2016 年第二季的擬制(pro forma)營收 6.729 億美元增加 6.4%。
Adjusted earnings per diluted share was $0.66 for the second quarter this year compared with $0.73 last year. As detailed in the press release, on a pro forma basis, adjusted EPS increased 10% for the second quarter of 2017 from pro forma adjusted EPS of $0.60 for the second quarter of 2016. Adjusted EPS for the latest quarter excludes transaction-related expenses of $9.1 million and debt extinguishment cost of $0.8 million. For the second quarter of 2016, adjusted EPS excludes transaction-related expenses of $6.1 million and a gain on foreign currency derivatives of $98,000.
今年第二季調整後稀釋每股盈餘為 0.66 美元,去年為 0.73 美元。如新聞稿所述,以擬制基礎計算,2017 年第二季調整後 EPS 較 2016 年第二季擬制調整後 EPS 0.60 美元增加 10%。最新季度的調整後 EPS 排除 910 萬美元的交易相關費用及 80 萬美元的債務清償成本。2016 年第二季的調整後 EPS 排除 610 萬美元的交易相關費用,以及 9.8 萬美元的外匯衍生性金融工具收益。
Acadia's second quarter same facility revenue increased 6.5% from the second quarter of 2016, with a 4.6% increase in patient days and a 1.8% increase in revenue per patient day. Same facility revenue for the U.S. increased 7.8% from the second quarter of 2016, with a 6% increase in patient days and a 1.7% increase in revenue per patient day; while in the U.K., same facility revenue increased 4%, patient days increased 2.8% and revenue per patient day increased 1.1%. Same facility EBITDA margin was 26.4% compared with 26.7% for the second quarter of 2016.
Acadia 第二季同院所營收較 2016 年第二季增加 6.5%,其中病患日數增加 4.6%,每病患日營收增加 1.8%。美國同院所營收較 2016 年第二季增加 7.8%,其中病患日數增加 6%,每病患日營收增加 1.7%;而在英國,同院所營收增加 4%,病患日數增加 2.8%,每病患日營收增加 1.1%。同院所 EBITDA 利潤率為 26.4%,2016 年第二季為 26.7%。
Acadia's tax rate on adjusted income from continuing operations before income taxes was 24.8% for the second quarter of 2017 compared with 21.7% for the second quarter of 2016. Acadia's operating cash flow from continuing operations was $131 million for the second quarter of 2017.
Acadia 2017 年第二季持續營運之調整後稅前所得的稅率為 24.8%,2016 年第二季為 21.7%。Acadia 2017 年第二季來自持續營運的營業活動現金流量為 1.31 億美元。
Turning to our financial guidance. And as announced in yesterday afternoon's news release, we adjusted our 2017 financial guidance within the previously established range, including: revenue in the range of $2.85 billion to $2.87 billion; adjusted EBITDA in the range of $628 million to $635 million; and adjusted diluted EPS in the range of $2.42 to $2.47. This guidance assumes an exchange rate of $1.25 per British pound sterling and a tax rate of approximately 25%. Our financial guidance does not include the impact from any future acquisitions and transaction-related expenses.
接著談我們的財務指引。如同昨日下午新聞稿所宣布,我們在先前既定區間內調整了 2017 年財務指引,包括:營收介於 28.5 億至 28.7 億美元;調整後 EBITDA 介於 6.28 億至 6.35 億美元;以及調整後稀釋 EPS 介於 2.42 至 2.47 美元。此指引假設匯率為每 1 英鎊兌 1.25 美元,且稅率約為 25%。我們的財務指引未包含任何未來併購及交易相關費用的影響。
This concludes our prepared remarks this morning, and thank you for being with us. I will now ask Lauren to open the floor for your questions.
以上為我們今早預先準備的說明,感謝各位與會。我現在請 Lauren 開放提問。
Operator
Operator
(Operator Instructions) Our first question comes from Brian Tanquilut with Jefferies.
(接線員指示) 我們的第一個問題來自 Jefferies 的 Brian Tanquilut。
Brian Gil Tanquilut - Equity Analyst
Brian Gil Tanquilut - Equity Analyst
Brent or Joey, just first question for me. You narrowed the guidance ranges, and I think that the -- there has been a lot of question overnight for investors on whether there's anything to read into the revenue guidance midpoint being slightly below the previous midpoint. Is there anything you guys would be able to provide in terms of color and how you are thinking about the revenue guidance adjustment?
Brent 或 Joey,我這邊先問第一個問題。你們縮窄了財測區間,我想投資人昨晚有很多疑問:是否需要解讀營收財測的中位數略低於先前的中位數。你們能否提供一些說明,談談你們如何看待這次營收財測調整?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Brian, great question. No, there's not. That at the beginning of the year, we set ranges, as we always do and in the middle of the year, we just tighten them up a little bit, and that's all we did here was tighten them up a little bit. There's nothing other than just -- we're just narrowing the ranges from the beginning of the year. And as you saw in our second quarter results, we're doing terrific, and we expect that to continue for the last 6 months.
Brian,問得很好。不,沒有。年初我們一如既往地設定區間;到了年中,我們只是把區間稍微收緊一點,而這次做的也只是稍微收緊。沒有其他原因——我們只是把年初的區間縮窄。而且如你在第二季業績所見,我們表現非常出色,並預期這種表現會在接下來 6 個月持續。
Brian Gil Tanquilut - Equity Analyst
Brian Gil Tanquilut - Equity Analyst
I appreciate that, Joey. And then my next question, we're obviously seeing a lot of headlines on opioid addiction and how the government's trying to fund and increase the focus on that. So do you mind just giving us some color on what your view is, in terms of how Acadia could directly or indirectly benefit from all the funds being thrown at this problem? And then also, what your exposure is to methadone, for example? Is that one way to treat this problem and what your exposure is there? Just trying to figure out if -- how big of a benefit could this be for Acadia?
謝謝你,Joey。接著我的下一個問題:我們顯然看到很多關於阿片類藥物成癮的新聞標題,以及政府正試圖提供資金並加大關注。所以你介意給我們一些看法嗎?就 Acadia 可能如何直接或間接受益於投入到這個問題上的資金而言。另外,例如美沙酮(methadone)方面,你們的曝險有多大?這是否是一種治療方式?你們在這方面的曝險如何?我只是想了解——這對 Acadia 的潛在好處可能有多大?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Well, as you know, the Cures Act and the money there is divided into 2-year increments. And states are beginning to work through that process of how they're going to treat more of the patients in their states for the opiate addiction. Now we've had positive results in one large state already, where we're going to get through our system about $4 million a year, in addition from the funds that have been allocated. And now we won't -- that won't all drop to the bottom line. We'll take care of patients. And then there'll be a couple of other facilities in this network that will be sharing in this money. But states are beginning to work through this issue, and the first state to get through it and to allocate some money, we were able to get over $4 million for that.
嗯,如你所知,《Cures Act》(治癒法案)以及其中的資金是以每 2 年為一個增量來分配的。各州正開始推進流程,思考他們將如何為州內更多阿片類成癮患者提供治療。目前我們已在一個大型州看到正面結果,透過我們的系統每年將增加約 400 萬美元,這是來自已分配的資金。當然,我們不會——這些不會全部直接落到淨利。我們會照護病患。此外,這個網絡中還會有其他幾家機構共同分配這筆資金。但各州正開始處理這個議題,而第一個完成流程並分配部分資金的州,我們就能取得超過 400 萬美元。
Operator
Operator
Our next question comes from Whit Mayo with Robert Baird.
我們的下一個問題來自 Robert Baird 的 Whit Mayo。
Benjamin Whitman Mayo - Senior Research Analyst
Benjamin Whitman Mayo - Senior Research Analyst
Maybe just first on the volumes. Any pockets of strength to call out across any of your U.S. businesses? And maybe if you could just broadly comment on payer mix trends.
先從量的部分談起。你們在美國各項業務中,有沒有哪一些領域特別強勁值得點出?另外,若可以的話,請你們概括評論一下付款方組合(payer mix)的趨勢。
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Payer mix is very stable from the first quarter. And the strength has been in our acute business, but it's been in all our businesses. But acute, once again, that's where we've been concentrating on the bed builds. It continued to be a little higher percent of the patient days generated for the company. And so everything else is pretty stable, and we think the outlook is very positive. And as we have worked through the second quarter results and thought about it, it's very important if you're going to put up these -- if you're going to meet the needs of the local community and put up good same-store growth numbers, you've got to get your beds built. And that's what we've been doing and we will build more than 800 beds this year, and that's coming off of about same number for last year. So we're in a good position to continue to build acute beds but we will build some beds in all areas of service and just focus on meeting the needs of the local community. So we feel pretty good right where we're at.
付款方組合相較第一季非常穩定。而強勁表現出現在我們的急性照護業務,但其實各項業務都表現不錯。不過急性照護再次成為重點,因為我們一直把重心放在增建床位。它持續在公司所產生的病患日(patient days)中占比略高。其他方面都相當穩定,我們認為展望非常正面。而在我們檢視第二季結果並思考後,如果你要達成——如果你要滿足在地社區需求並交出良好的同店成長數字,你就必須把床位建起來。這正是我們一直在做的;今年我們將增建超過 800 張床位,這是延續去年大約相同的增建規模。因此,我們處於良好位置,能持續增建急性床位;同時我們也會在所有服務領域增建一些床位,並專注於滿足在地社區需求。所以我們對目前的狀況感覺相當不錯。
Benjamin Whitman Mayo - Senior Research Analyst
Benjamin Whitman Mayo - Senior Research Analyst
Okay. And my next question, Brent, any just update on the U.K. operations, how they're trending versus your expectation? I'm just really more curious now, after the election, any change with the NHS or staffing changes? Just -- we've seen some hiccups from some other nonbehavioral providers. I'm not sure this applies to you, but just any general observations on the current environment over there would be helpful.
好的。我的下一個問題,Brent,能否更新一下英國營運的情況?它們相對於你們的預期走勢如何?我主要是好奇,選舉之後,NHS 是否有任何變化或人力配置上的改變?只是——我們看到一些其他非行為健康服務提供者出現一些小波折。我不確定這是否適用於你們,但若能分享對那邊目前環境的整體觀察會很有幫助。
William Brent Turner - President
William Brent Turner - President
I think, as you see from our second quarter numbers, the U.K. improved for us in the second quarter over the first quarter. And our expectations are consistent there with what we said is that we're going to get incremental improvements through the U.K. over the balance of the year. We don't expect that market to be exactly in line with the attractive metrics of the U.S., but it's not far off. And we are not seeing just massive issues around some of the election issues. I mean, the behavioral health needs in the U.K. are not going away. And so ultimately we believe, short term and long term, our facilities and our operations are well positioned to meet the needs over there. And we see good funding streams for that, again, both in the short and the long term.
我想,從我們第二季的數字你可以看到,英國在第二季相較第一季對我們而言有所改善。而我們的預期也與先前所說一致:今年剩餘期間英國業務會逐步帶來增量改善。我們不預期那個市場能完全達到美國那樣吸引人的指標,但差距並不大。而且我們沒有看到因選舉相關議題而出現非常重大的問題。我的意思是,英國的行為健康需求不會消失。因此,無論短期或長期,我們相信我們的機構與營運都已做好良好布局,能滿足那邊的需求。而且我們也看到良好的資金來源,同樣地,無論短期或長期都是如此。
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
And Whit, I'll just add that the new team we put together, that Ron Fincher and David Duckworth put together in December -- both of those guys just got back from the U.K., and we're very pleased with where we are there and the team we've got assembled there. So -- it will follow -- it will be a little bit slower growth than what the U.S. is because of -- the metrics here are so strong. And we're very pleased with our investment in the U.K. and we expect them to continue, just at a little slower pace.
Whit,我再補充一下:Ron Fincher 和 David Duckworth 在 12 月組建的新團隊——那兩位剛從英國回來,我們對目前在那邊的進展以及所建立的團隊非常滿意。所以——它會跟隨——相較美國,成長會稍微慢一些,因為——美國這邊的指標實在太強。我們對在英國的投資非常滿意,也預期他們會持續推進,只是步調會稍微慢一點。
Operator
Operator
We'll take our next question from A.J. Rice with UBS.
我們的下一個問題由 UBS 的 A.J. Rice 提問。
Albert J. Rice - MD and Equity Research Analyst, Healthcare Facilities
Albert J. Rice - MD and Equity Research Analyst, Healthcare Facilities
Maybe just first on, I know you made the comment about the deal pipeline still being strong. I know there was some discussion about how quick you might be able to redeploy the Priory divestiture assets or cash and larger transactions versus smaller ones. Any further commentary along those lines?
先問第一個:我知道你提到交易案源(deal pipeline)仍然很強。我也知道之前有一些討論,關於你們能多快把 Priory 出售(divestiture)所取得的資產或現金重新部署到大型交易或較小型交易上。在這方面還有沒有進一步的評論?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
We have active discussions underway to do that. And we're very busy looking at acquisitions, both one-off and larger transactions, A.J. And I can't comment any further other than it's -- we're working hard on those opportunities.
我們正在進行積極的討論來做到這點。而且我們非常忙於評估併購,包含單一標的(one-off)以及較大型的交易,A.J.。除了——我們正在努力推進這些機會之外,我無法再多做評論。
Albert J. Rice - MD and Equity Research Analyst, Healthcare Facilities
Albert J. Rice - MD and Equity Research Analyst, Healthcare Facilities
Okay, okay. Obviously, not as much for you, but to some degree, there's been discussion around the industry about the tightness of labor supply and finding both psychiatrists and nurses. Any update on your thinking? What are you seeing in terms of turnover rates, vacant job postings and so forth and wage updates and so forth?
好,好。顯然對你們影響沒那麼大,但某種程度上,業界一直在討論勞動供給吃緊,以及尋找精神科醫師與護理人員的困難。你們對此看法有沒有更新?就離職率、職缺空缺(vacant job postings)等情況,以及薪資更新等方面,你們看到了什麼?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
We still have -- as we've mentioned for the past couple of years, we have some isolated markets where it's a little tougher to find the nurses or the psychiatrists. But we've got a great team in recruitment. And we have provided additional resources this year into that department, and we'll see them -- those resources be very fruitful. So the labor market is tight, but we've been able, Ron and his team and the recruitment department that reports to Ron, have been able to find the personnel that we need to continue to put up 6% same-store patient day growth here in the U.S. So I think we can continue to do that and find the people. Their -- on the salary wage pressures, it's in the 2% to 3% is what we're seeing for wage increases. And so -- but we want to be competitive in all our markets with -- we compete with the med/surg hospitals and other health care providers. So we think we're in a good position and have been able to work through it for these past several years.
如同我們在過去幾年提到的,我們仍然有一些零星的市場,在那裡要找到護理師或精神科醫師會比較困難。但我們的招募團隊非常出色。而且今年我們也在該部門投入了額外資源,我們將會看到——那些資源帶來非常豐碩的成果。所以勞動市場確實緊俏,但我們已經能夠——Ron 和他的團隊,以及向 Ron 匯報的招募部門——找到我們所需的人員,以便在美國持續達成 6% 的同店病患日數成長。因此我認為我們可以持續做到,並找到合適的人才。至於薪資工資壓力,我們看到的薪資增幅大約在 2% 到 3%。因此——但我們希望在所有市場都保持競爭力——我們的競爭對手包括內外科(med/surg)醫院及其他醫療服務提供者。所以我們認為我們處於良好位置,並且在過去幾年已經能夠順利應對。
Operator
Operator
Our next question comes from Ralph Giacobbe with Citi.
我們的下一個問題來自 Citi 的 Ralph Giacobbe。
Ralph Giacobbe - Director
Ralph Giacobbe - Director
Any way to parse out the impact from IMD Exclusion or maybe whether you think that's kind of aiding the strong U.S. volume or if that's still on the come? And if you sort of feel that momentum of that can sort of be a driver into the back half?
有沒有辦法拆解一下 IMD Exclusion 的影響?或者你們是否認為這在某種程度上正在推動美國強勁的量能,還是說這個影響仍在逐步顯現?以及你們是否覺得這股動能可以成為下半年的一個驅動因素?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
The only thing I have in front of me is the payer mix, which we disclosed inside the quarterly report, and it's very stable. Medicaid, just Medicaid with -- in total is up a little, 0.50 basis points from the first quarter to the second quarter. And we think it's going to stay in that range. And so our payer mix is very, very stable. And so the IMD, I think, is already factored in and we don't see -- we just think it's a very stable payer mix.
我手邊唯一有的資料是我們在季度報告中揭露的付款方組合(payer mix),而且非常穩定。Medicaid——僅就 Medicaid 而言——整體從第一季到第二季小幅上升了 0.50 個基點。我們認為它會維持在這個區間。因此我們的付款方組合非常、非常穩定。所以我認為 IMD 已經被反映在內,我們沒有看到——我們只是認為付款方組合非常穩定。
Ralph Giacobbe - Director
Ralph Giacobbe - Director
Okay, fair enough. And then there's been a lot on the length of stay pressure in the market, particularly in the U.S. [Is it -- did you] see a whole lot of that in this quarter? I guess, how do you view length of stay? Do you expect there to be kind of some pressures on a go-forward basis or just your general thoughts on length of stay?
好的,了解。另外,市場上對住院天數(length of stay)的壓力討論很多,尤其是在美國。[你們是否——你們]在本季看到很多這種情況?我想問,你們如何看待住院天數?你們是否預期未來會有一些壓力,或是你們對住院天數的一般看法?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Length of stay for us has been very stable. And the length of stay, the utilization review process has always been tough, and we've always done well with that process. Our length of stay, if it does slightly decline, is more of a function of more acute patients who have shorter length of stays versus our specialty facilities or our residential facilities. So any decline so far this year, and really last year, was basically just because we have more acute patients because we built all those beds. So our length of stay is very stable and very strong.
我們的住院天數一直非常穩定。而且住院天數方面的利用審查(utilization review)流程一向很嚴格,我們也一直在這個流程上表現良好。如果我們的住院天數略有下降,更多是因為急性期病患增加——他們的住院天數較短——相較於我們的專科機構或住宿型(residential)機構。所以今年到目前為止的任何下降,實際上去年也是,基本上只是因為我們新增了很多床位,導致急性期病患更多。因此我們的住院天數非常穩定且表現強勁。
Operator
Operator
Our next question comes from John Ransom with Raymond James.
我們的下一個問題來自 Raymond James 的 John Ransom。
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
A couple of things. Joey, how long do you have line of sight looking out over the next, say, 3 to 5 years that you can continue to add beds in the U.S. at this 800 level?
有幾點問題。Joey,展望未來例如 3 到 5 年,你們能看到多長的能見度,讓你們在美國仍能以每年 800 張床這個水準持續新增床位?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
I see it accelerating, John. I don't -- so not only are we going to maintain it, I think there's an opportunity that we could actually build more beds. So -- over the next 3 to 5 years. So if you were to average it, I think it's -- over the next 3 to 5 years, it's going to be above 800. We see the demand and access these patients need. And our people in the field, Ron has -- Ron Fincher, once again, and the team there that he's put together. And whenever we go over the bed build report, that's an exciting time of the month because we see all the opportunities for the next 18 months. So we're very bullish on the next 3 to 5 years.
我看到的是加速,John。我不——所以我們不僅會維持,我認為其實有機會建更多床位。所以——在未來 3 到 5 年。如果取平均,我認為——在未來 3 到 5 年,會高於 800。我們看到病患需求以及他們所需要的可近性(access)。而我們在第一線的人員,Ron——再次提到 Ron Fincher——以及他所組建的團隊。每當我們檢視床位建置報告時,那都是每個月最令人振奮的時刻,因為我們能看到未來 18 個月的所有機會。所以我們對未來 3 到 5 年非常樂觀。
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
Great. Secondly, just hypothetically, let's say, there was a deal somewhere north of $500 million in the U.S. Other than -- would you be inclined to raise equity at that point to keep the leverage? Or would you look at maybe sale-leaseback some of your mature facilities? How are you thinking through -- or should we just worry about that bridge if you decide to cross it?
很好。第二個問題,假設性地說,如果在美國有一筆超過 5 億美元的交易。除了——你們是否會傾向在那個時點增發股權以維持槓桿水準?或者你們會考慮把一些成熟機構做售後回租(sale-leaseback)?你們是如何思考——還是我們應該等你們真的要過那座橋時再擔心?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
I think, as you've seen, we've always done in the past is when we come up to large acquisitions, we look at what is the best way to finance that transaction to give return to all of our shareholders. And I think if it was a transaction the size of what you described, we pretty much know the sellers there, and they -- it's possible that they'd take some of the purchase price and shares of Acadia. So -- but once again, we would look at the balance sheet at the time of the transaction and find the best, most efficient way to finance it to return value to our shareholders.
我認為,如你所見,我們過去在面對大型併購時一向會評估,採用何種方式為交易融資,才能為所有股東帶來回報。我想如果是你描述的那種規模的交易,我們大致也知道那邊的賣方是誰,而且——他們有可能會接受部分對價以 Acadia 的股票支付。所以——但再次強調,我們會在交易當下檢視資產負債表,並找出最佳、最有效率的融資方式,以為股東創造價值。
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
Fair enough. And then my last question, and this is just more kind of accounting minutiae, as you start to build these de novos, on your reported financials, are you going to add back startup losses into your adjusted EPS and adjusted EBITDA numbers?
了解。那我最後一個問題,這比較偏會計細節。當你們開始建置這些 de novos(新設據點)時,在你們對外報告的財務數字中,是否會把開辦期虧損(startup losses)加回到調整後 EPS 與調整後 EBITDA?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
We have no intention to do that. That's something we'll think about, John. We have no intention to do that. If it becomes something that we think we disclose, I think, in the past, we just verbally disclose it.
我們沒有這樣做的打算。這是我們會再思考的事情,John。我們沒有這樣做的打算。如果它成為我們認為需要揭露的事項,我想過去我們只是口頭揭露。
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
Okay. And I think the last number you gave was 20. Is that still the right number? Or has that number changed -- as in de novo projects?
好的。我記得你上次給的最後一個數字是 20。那仍然是正確的數字嗎?還是那個數字已經改變——就 de novo 專案而言?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Oh, John, it could be even more -- it could be more than 20.
噢,John,甚至可能更多——可能超過 20。
Operator
Operator
Our next question goes to Ryan Daniels at William Blair.
我們的下一個問題轉到 William Blair 的 Ryan Daniels。
Ryan Scott Daniels - Partner and Healthcare Analyst
Ryan Scott Daniels - Partner and Healthcare Analyst
I want to do a follow-up on the U.K. operations. I know you said the expectation, Brent, is for that to continue to improve. But number one, how close are you on achieving the $20 million in annualized synergies as of this quarter? And then number two, with a fully integrated care continuum in the U.K., I'm curious if you're starting to see more referrals or if it's helping your volumes by keeping the patient in the system longer now that, that's been integrated?
我想追問一下英國(U.K.)的營運。我知道你說過,Brent,預期那邊會持續改善。但第一,截至本季,你們距離達成每年年化 2,000 萬美元的協同效益(synergies)有多接近?第二,在英國已完整整合的照護連續體(care continuum)之下,我很好奇你們是否開始看到更多轉介(referrals),或是這種整合是否透過讓病患在系統內停留更久而提升你們的量能?
William Brent Turner - President
William Brent Turner - President
Okay, Ryan. I think David can give us the exact -- but we're on track on the synergies, making continuous -- continuing progress to meet or exceed the $20 million in synergy savings there out of that with -- now that we've been able to integrate the 2 businesses and work those. I think we actually have been positioned well across the continuum, even back to our former acquisition in 2014. And so again, I think our belief there is that our positioning across the different levels of care and our commitment to invest capital in the U.K. and add beds where needed, really positions us well to keep those patients in our system and really see them throughout the process. So we think there's good stability there from that standpoint.
好的,Ryan。我想 David 可以給我們精確數字——但我們在協同效益方面進度如期,持續——持續推進,以達成或超越那邊 2,000 萬美元的協同節省;在我們能夠整合這兩個業務並加以運作之後。我認為我們其實在整個連續體上的布局一直不錯,甚至可以追溯到我們 2014 年的前一次收購。因此再次強調,我們相信我們在不同照護層級的布局,以及我們承諾在英國投入資本、在需要之處增加床位,確實讓我們能更好地把病患留在我們的體系內,並在整個流程中持續照護他們。所以從這個角度來看,我們認為那邊具有良好的穩定性。
David M. Duckworth - CFO, CAO and Controller
David M. Duckworth - CFO, CAO and Controller
And Ryan, this is David. I'll just confirm, our team in the U.K. has done a fantastic job on the integration. We are still on track to achieve the $20 million synergy target in the second half of the year.
Ryan,這裡是David。我先確認一下,我們英國團隊在整合方面做得非常出色。我們仍按計畫在今年下半年達成2,000萬美元的協同效益目標。
Ryan Scott Daniels - Partner and Healthcare Analyst
Ryan Scott Daniels - Partner and Healthcare Analyst
Okay, perfect. And then as my follow-up, just a quick question on the same-store EBITDA margins. Obviously, a nice improvement versus the trend in the first quarter, so congrats on that. But still curious, given the strong US same-store growth, if you anticipate seeing kind of better margin expansion in the future. I know it was down about 20 basis points year-over-year this quarter.
好的,完美。接著我追問一下,同店EBITDA利潤率的問題。很明顯,相較第一季的趨勢有不錯的改善,恭喜。但我仍好奇,考量美國同店成長強勁,未來是否預期會看到更好的利潤率擴張。我知道本季年對年大約下滑了20個基點。
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
The 20-basis point decline over last year, last year's number was the highest this company has ever had. So the 28.4, we're absolutely pleased with that number. And so there's not a lot of concern here about the 20 basis points. That is more a factor of last year, this was the best quarter we've ever had -- that we ever had on that margin number, I think, or since 2013 maybe. And the 28.4, that's pretty strong.
相較去年下滑20個基點,而去年的數字是公司有史以來最高。所以對於28.4%這個數字,我們非常滿意。因此對這20個基點並沒有太多疑慮。這更多是去年的因素;去年那一季是我們在該利潤率指標上表現最好的一季——我想是我們有史以來,或至少自2013年以來。而28.4%已經相當強勁。
Operator
Operator
Our next question comes from Ann Hynes with Mizuho Securities.
下一個問題來自Mizuho Securities的Ann Hynes。
Ann Kathleen Hynes - MD of Americas Research
Ann Kathleen Hynes - MD of Americas Research
Going back to the U.K., can you talk about the reimbursement environment over there and what you expect for the next 12 months? Because I think you just finished the negotiations.
回到英國,你能談談那邊的給付/報銷環境,以及你們對未來12個月的預期嗎?因為我想你們剛完成談判。
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Yes, Ann, this is Joey. And good to talk to you this morning. We are averaging more than 1% increase in the pricing over there for this year. And we would expect that to be similar next year. And one benefit that we're getting is that the NHS, our contracts directly with the NHS, that percentage is declining, and we're negotiating more with the local communities, agencies that control the rates. And we're doing okay there. And so we're -- we think next year will look a lot like this year, over 1% increase in the rates.
是的,Ann,我是Joey。很高興今天早上和你通話。我們今年在那邊的價格平均上調超過1%。我們預期明年也會類似。另外我們得到的一個好處是:NHS——我們與NHS直接簽約的合約占比正在下降,我們更多是與掌控費率的地方社區與機構進行談判。我們在那方面進展還不錯。因此我們認為明年會很像今年,費率上調超過1%。
Ann Kathleen Hynes - MD of Americas Research
Ann Kathleen Hynes - MD of Americas Research
Okay, great. And just staying on the U.K. I know there's some thought with Brexit that the NIH could start outsourcing more of their beds to the private payers. Are you seeing that at all yet? Or do you expect that?
好的,很好。再延伸英國的問題,我知道有些人認為因為脫歐,NHS可能會開始把更多床位外包給民營付費方。你們現在有看到這種情況嗎?或你們預期會發生嗎?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Our team over there is cautiously optimistic that we think the NHS will close more of their beds. And when that does occur, they look to us. And they've already given us some beds that they need, and the service lines that they need, that we are building for them. And right now, I think we have more than 200 beds that are in that category, where we're trying to meet the NHS's needs for these services. So we have a good relationship with NHS. And they know we have access to capital. And they know that we will build as necessary to meet the needs if they continue to close their beds.
我們那邊的團隊抱持審慎樂觀,認為NHS會關閉更多自有床位。而一旦發生,他們就會轉向我們。他們已經交給我們一些他們需要的床位,以及他們需要的服務線,我們正在為他們建置。目前我想我們有超過200張床位屬於這一類,也就是我們正努力滿足NHS對這些服務的需求。所以我們與NHS關係良好。他們知道我們有資本可用。他們也知道,如果他們持續關床、需求存在,我們會視需要興建以滿足需求。
Ann Kathleen Hynes - MD of Americas Research
Ann Kathleen Hynes - MD of Americas Research
Okay, great. Can I have one follow-up question, I think, that John asked? On the de novo expenses, is it $20 million that's embedded in guidance of startup costs?
好的,很好。我可以追問一個問題嗎?我想是John剛剛問的。關於新設(de novo)費用,指引中是否已包含2,000萬美元的啟動成本?
William Brent Turner - President
William Brent Turner - President
No, no, no. John jumped to the overall outlook for de novo and joint venture opportunities with medical surgical hospital systems. And so our pipeline is more than 20, and it's nothing to do with $20 million of expenses.
不是,不是,不是。John是直接跳到對新設以及與醫療外科醫院體系合資機會的整體展望。所以我們的案源管線超過20個,這跟2,000萬美元的費用完全無關。
David M. Duckworth - CFO, CAO and Controller
David M. Duckworth - CFO, CAO and Controller
No.
不是。
Ann Kathleen Hynes - MD of Americas Research
Ann Kathleen Hynes - MD of Americas Research
Okay. So what are the expenses embedded in guidance? Or the startup costs, I should say?
好的。那麼指引中包含的費用是多少?或者我應該說,啟動成本是多少?
David M. Duckworth - CFO, CAO and Controller
David M. Duckworth - CFO, CAO and Controller
We do have 3 facilities coming on in the second half of the year. Just ballpark number, they may be a couple million of startup losses that we would incur in the second half of the year. But just thinking back to the last few years, we have opened facilities every year. So we think about that for us is just a normal part of the year because we just continue to open those new facilities. We had it last year and we may have it in the second part of this year.
我們在今年下半年會有3家機構啟用。粗略估計,我們在下半年可能會承擔幾百萬美元的啟動期虧損。但回想過去幾年,我們每年都會開設新機構。所以對我們而言,這只是年度中的正常一部分,因為我們持續開設這些新機構。去年有,今年下半年也可能會有。
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
And if we think it's material, we will disclose the number on the calls.
如果我們認為金額具重大性,我們會在電話會議中揭露該數字。
Operator
Operator
We'll take our next question from Chris Rigg with Deutsche Bank.
下一個問題由德意志銀行的Chris Rigg提問。
Christian Douglas Rigg - Research Analyst
Christian Douglas Rigg - Research Analyst
Just wanted to ask about capital deployment. Obviously, you're talking about robust M&A pipeline and same on the organic bed development side. How do you think about deploying that capital versus the return you get? Do you get a better return on the M&A versus the organic beds?
我想問一下資本配置。很明顯你們提到強勁的併購(M&A)案源管線,以及同樣在自建床位開發方面也很積極。你們如何思考資本投放與所獲得的報酬之間的取捨?併購的報酬會比自建床位更好嗎?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
No. Obviously, the organic bed is incremental patients to us, in that we spread the overhead of that facility across those extra patients. So always, with us, the best return is put them in a bed we have. If not, build the bed to the existing facility and then look for good acquisitions that meet those characteristics of growth and in a market that can grow and that has been underserved. So that is how we look -- that is how capital is deployed in the company.
不會。很明顯,自建床位對我們而言是新增病患,因為我們可以把該機構的間接費用分攤到這些額外病患上。所以對我們來說,最好的報酬永遠是把病患安排到我們既有的床位。如果不行,就在既有機構擴建床位,然後再尋找符合成長特性、位於可成長且供給不足市場的優質收購案。這就是我們看待——也就是公司資本配置的方式。
Christian Douglas Rigg - Research Analyst
Christian Douglas Rigg - Research Analyst
Right, okay. And then with regard to the M&A pipeline, do you see more opportunity on the acute sort of behavioral side? Or is it substance abuse or residential treatment? Or where do you see a majority of the opportunities right now?
了解,好。那關於併購案源管線,你們看到更多機會是在急性期的行為健康領域嗎?還是物質濫用或住宿式治療?或者目前大多數機會集中在哪裡?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
We will continue to concentrate on the acute side. It would be the one-off transactions that might be on the addiction side. So it's more on the acute side, maybe one-offs on the addiction, maybe one-off on the CTC opportunity that we have. So there is too many substance abuse companies that have popped up over the last 5 years that did not have a long enough track record for our due diligence. So I turn down probably one a month of those just because they don't get through the due diligence.
我們會持續聚焦在急性期領域。可能會有一些單筆交易落在成癮領域。所以主要還是在急性期,成癮方面可能有零星個案,另外我們的CTC機會也可能有零星個案。過去5年冒出太多物質濫用公司,但其營運紀錄不夠長,無法通過我們的盡職調查。所以我大概每個月會拒絕一個,原因就是它們無法通過盡職調查。
Christian Douglas Rigg - Research Analyst
Christian Douglas Rigg - Research Analyst
Right. Okay. And then just one follow-up here. And sorry, it's just not clear to me. But when I think about the very modest margin pressure domestically overlaid with the startup costs from the new beds, is that factoring in to the same-store margin pressure? Or is that not the case?
了解。好的。再追問一個。抱歉,我有點不太清楚。當我把美國本土非常溫和的利潤率壓力,再加上新床位的啟動成本一起考量時,這是否已反映在同店利潤率的壓力之中?還是並非如此?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
That is the case because everything is now in the U.S. same-store numbers.
是的,因為現在所有內容都包含在美國同店數據裡。
Operator
Operator
We'll take our next question from Kevin Fischbeck with Bank of America.
下一個問題由美國銀行的Kevin Fischbeck提問。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
I guess, sequentially, the revenue acceleration on a same-store basis in the U.S., obviously, a little bit of a volume pickup. But really, just more on rate. Is there anything that would highlight there around rates?
我想就環比來看,美國同店營收增速加快,顯然有一點量的回升。但主要其實是費率帶動。在費率方面,有沒有什麼重點可以說明?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
It's a focus of operations to be prompt in their renegotiation of the contracts. And we've been getting some positive increases. So -- and so that is what's happening to the rate increases, is that we do have more awareness, review, expectation that they're making sure they're renegotiating their contracts more timely.
在營運上,我們的重點之一是要迅速推動合約的重新談判。而我們也取得了一些正向的調升。所以——關於費率調升目前的情況是,我們確實有更高的關注度、審視與期待,確保他們能更及時地重新談判合約。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
Okay. And I guess, just go back to that startup loss question. That's a couple of million dollars. Is that couple of million dollars per site that you're assuming [in the guidance]? Or a couple of million dollars overall [in the share of] losses in the second half?
好的。我想再回到那個新設點虧損的問題。那大約是幾百萬美元。你們在[指引中]假設的是每個據點幾百萬美元嗎?還是下半年整體[分攤的]虧損合計幾百萬美元?
David M. Duckworth - CFO, CAO and Controller
David M. Duckworth - CFO, CAO and Controller
That's overall in the second half of the year.
那是下半年整體的數字。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
Okay. Is that weighted to Q3 or Q4?
好的。那是偏向第三季還是第四季?
David M. Duckworth - CFO, CAO and Controller
David M. Duckworth - CFO, CAO and Controller
No, it would be spread over the quarter. Part of that is just the timing of when we're bringing these facilities on. We think that over the first year, they're breakeven. But just happening late in the year like this, the 6-month period would absorb more of those losses. But that's for all 3 combined, Kevin.
不,會分散在各季。其中一部分只是我們啟用這些設施的時間點。我們認為在第一年內會達到損益兩平。但像這樣在年底才發生,6 個月期間就會吸收較多的虧損。不過那是三家合計的,Kevin。
Operator
Operator
Our next question comes from Charles Haff with Craig-Hallum.
下一題來自 Craig-Hallum 的 Charles Haff。
Charles Edward Haff - Senior Research Analyst
Charles Edward Haff - Senior Research Analyst
In terms of the 91 beds you added this quarter and the 250 you expect next quarter, do you have an approximate split between U.S. and U.K. there?
就本季新增的 91 張床位,以及下季預期新增的 250 張床位而言,美國與英國大概各占多少?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Yes, we do. Do you have that, David?
是的,我們有。David,你那邊有數字嗎?
David M. Duckworth - CFO, CAO and Controller
David M. Duckworth - CFO, CAO and Controller
Yes, we do. Most of the beds this quarter were in the U.S., 80 of the 91. In the first quarter, 30 of the 82 were in the US. And we'll see, for the second half of the year, we will obviously, with the new facilities in the U.S., we will see most of those beds coming on in the U.S.
有的。本季大多數床位在美國,91 張中有 80 張在美國。第一季 82 張中有 30 張在美國。而下半年,顯然隨著美國的新設施啟用,我們會看到大多數新增床位都會在美國上線。
Charles Edward Haff - Senior Research Analyst
Charles Edward Haff - Senior Research Analyst
Okay, great. And the 3 JV openings that you have in the second half of this year, can you just remind us which facilities those are, and how many beds they will be and when they're going to open?
好的,很棒。另外,你們今年下半年有 3 個合資(JV)開業案,能否提醒我們分別是哪幾個設施、各有多少床位,以及何時開業?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Well, the 3 facilities are located in Louisiana, Virginia and Arkansas. There's probably 200 beds for those 3 facilities. So they equal about 70 beds apiece.
這 3 個設施分別位於路易斯安那州、維吉尼亞州與阿肯色州。這 3 個設施合計大約 200 張床位。所以平均每家大約 70 張床位。
Charles Edward Haff - Senior Research Analyst
Charles Edward Haff - Senior Research Analyst
Perfect. And then on the labor side of things, have you found that you're having to use signing bonuses for some of those pockets where you're seeing some labor challenges?
完美。那在人力方面,對於你們看到有些人力挑戰的區域,你們是否發現需要使用簽約獎金?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Not for the nurses or the medical, other medical individuals that we might need in the hospital. Where we see signing bonuses, which has been customary for years ever since I was at HCA for physicians, that is just a part of the package that goes when you recruit a physician that there's usually a signing bonus.
對於護理人員或我們在醫院可能需要的其他醫療人員,不需要。我們看到的簽約獎金——這些年來一直是慣例,從我在 HCA 的時候就是如此——主要是針對醫師;招募醫師時,通常薪酬方案的一部分就會包含簽約獎金。
Charles Edward Haff - Senior Research Analyst
Charles Edward Haff - Senior Research Analyst
Okay, but not for the nurses? You're not using those yet?
好的,但護理人員沒有?你們還沒有用那些?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
No. And to have no intentions of doing that. Now I can't say that -- Montana might be using it but 99% of our facilities are not using that.
沒有。而且也沒有打算這麼做。當然我不能說完全不會——蒙大拿州可能在用——但我們 99% 的設施都沒有在用。
Operator
Operator
We'll take our next question from Gary Taylor at JPMorgan.
下一題我們請 JPMorgan 的 Gary Taylor。
Gary Paul Taylor - Analyst
Gary Paul Taylor - Analyst
I'd also say good job on the growth. I think you'll be the only provider whose trends improved sequentially this quarter. So that's really good to see. Two quick questions. One is just coming back to length of stay a little bit, which, in the U.S., obviously was almost flat. It was barely down. In the first quarter, it was more of an issue. It was down about 2.5%. And at the time, you said it was really nothing. It's normal fluctuation. And obviously, this quarter's results would suggest your intuition was correct there. But I'm just trying to think about your average length of stay actually is up a little bit, 16.5 days versus 16.1 in the first quarter. And you talked about more in-patient beds, acute beds coming into that. Obviously, the length of stay is lower there. So that wasn't quite a driver sequentially. So I guess, we're splitting hairs looking at pretty small changes. But given that UHS has talked about some managed Medicaid plans essentially approving fewer days in some states, I just wanted to come back, maybe ask that question directly. Have you seen any of the managed Medicaid plans being more stingy, in terms of number of days they're willing to approve?
我也想說你們成長做得很好。我想你們可能是本季唯一一家趨勢較前一季改善的服務提供者。所以很高興看到這點。兩個簡短問題。第一個是再回到住院天數(length of stay)這件事,在美國顯然幾乎持平。幾乎只是小幅下降。第一季比較是個議題。當時大約下降 2.5%。而你們當時說其實沒什麼。只是正常波動。而顯然本季結果顯示你的直覺是對的。但我在想,你們的平均住院天數其實略有上升,從第一季的 16.1 天到 16.5 天。你們也談到更多住院床位、急性床位加入。顯然那邊的住院天數較短。所以那並不是推動環比變化的因素。所以我想,我們是在對很小的變化吹毛求疵。但鑑於 UHS 提到某些州的管理式 Medicaid 計畫基本上核准的天數更少,我想再回來、也許直接問這個問題。你們是否看到任何管理式 Medicaid 計畫在核准天數方面變得更吝嗇?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
I have to go back. Utilization review has always been, in this industry, been very tough. And our length of stay, by payer, Medicare, we run about 12 to 13 days. And you can imagine, the patient is older and takes a little bit longer to respond to the treatment of the pharmacology and the social issues that they may have. Commercial, that's me and you. We would probably stay 7 to 8 days. And that's pretty much been what it's been in the industry. And then on Medicaid, they are pretty similar to the 7 to 8 days. So we might find a market where Medicaid might be 6 days, but we also might find a market where Medicaid is 9 days. And so the length of stay, as you mentioned, basically is flat. And it's very stable. And I will give you one peek on the length of stay inside the acute patient day length of stay, it was 9.2 in the second quarter of last year and then this year, it's 9.5. So that's slightly up. But the grand total is flat. So we don't -- hopefully, we don't see a reduction here or whatever. So we feel real good about the stability of the length of stay and even in the stability of the length of stay in the Medicaid population.
我得先回到一點:在這個產業裡,利用審查(utilization review)一直都非常嚴格。而我們按付款方來看住院天數:Medicare 我們大約是 12 到 13 天。你可以想像,病人年紀較大,對藥物治療的反應以及可能存在的社會問題,都會讓他們需要更長時間才能改善。商業保險,那就是你我這類人。我們大概會住 7 到 8 天。這基本上一直是產業的狀況。至於 Medicaid,他們也大致接近 7 到 8 天。所以我們可能會遇到某個市場 Medicaid 是 6 天,但也可能遇到某個市場 Medicaid 是 9 天。因此住院天數如你所提,基本上是持平的。而且非常穩定。我再給你一個關於急性病患日(acute patient day)住院天數的小資訊:去年第二季是 9.2 天,今年是 9.5 天。所以略有上升。但總體合計是持平的。所以我們不——希望不會看到這裡有任何下降之類的情況。因此我們對住院天數的穩定性非常有信心,甚至對 Medicaid 人口的住院天數穩定性也很有信心。
Gary Paul Taylor - Analyst
Gary Paul Taylor - Analyst
Okay. And then one quick one, one last one, if I could. Really appreciate the pro forma analysis taking out the divestitures and the FX because that certainly gets harder for us to do, as we move all the way down to EPS. But the question is, that pro forma EPS grew about 10% year-over-year. You've always been very willing to talk long term about top line growth, bed growth, facility growth, including today a little bit. How would you characterize what you think 3- to 5-year EPS growth should look like?
好的。然後如果可以的話,最後一個簡短問題。非常感謝你們提供剔除資產剝離與匯率(FX)的備考(pro forma)分析,因為當我們一路往下推到 EPS 時,這確實會更難處理。但問題是,那個備考 EPS 年增大約 10%。你們一直很願意談長期的營收成長、床位成長、設施成長,今天也稍微提到一些。你會如何描述你認為未來 3 到 5 年 EPS 成長應該呈現的樣貌?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
For the same group, the same facility group, Gary, I think we're going to grow it lower double-digit. Now what we want to do is add another 7% to 8% growth through acquisitions or through the joint ventures. So that's kind of how we're looking at it. And if we get that all accomplished in the year, then we're going to see EPS grow 18%, and you can add 2%. To do the range, I would do 16% to 20% would be the range, long term -- now this is looking out, kind of like what John did on bed builds looking out. This is us looking out over the next 3 to 5 years, that would be our expectations.
就同一個集團、同一個設施群而言,Gary,我認為我們會以較低的雙位數成長。接著我們想做的是,透過併購或合資再增加7%到8%的成長。所以我們大致是這樣看待的。如果我們在一年內把這些都完成,那麼我們將看到每股盈餘(EPS)成長18%,你還可以再加2%。若要給一個區間,我會給16%到20%作為長期區間——這是往外看,就像John先前談床位建置時那樣往外看。我們是在看未來3到5年,這會是我們的預期。
Operator
Operator
Our next question comes from Ana Gupte with Leerink Partners.
下一個問題來自Leerink Partners的Ana Gupte。
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
The question I have is you have a peer, and we only have the two of you to really observe, has had some regulatory coding issues, has had clinical staffing issues -- is now also speaking about a length of stay pressure from payers and the mix shifting to Medicaid and the like. And it's somewhat corroborated by some of the inner channel checks we've done, at least the last one. But you're not seeing it, which is really great, and you had a good quarter. Is this really that the pressures don't exist? Or is there something about being a best-in-class in-patient operator, [and you know], can you talk about what that might be that makes you able to avert that better?
我的問題是,你們有一家同業,而我們真正能觀察的其實就你們兩家,對方曾出現一些監管編碼問題,也有臨床人力配置問題——現在也在談到付款方帶來的住院天數壓力,以及組合轉向Medicaid等。而且這在我們做的一些通路內部查核中也多少得到印證,至少在最近一次是如此。但你們沒有看到這些情況,這真的很棒,而且你們這一季表現很好。這是否代表那些壓力其實不存在?或者是因為你們作為同級最佳的住院營運商,[你知道],能否談談可能是什麼因素讓你們更能避免這些問題?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Well, Ana, yes, we had a terrific quarter. Second quarter was terrific. But you can look at the year-to-date numbers, and they're terrific. We -- obviously, I think, our team is better than other people, other companies. Obviously, I think that. We cheerlead that. I think a factor that you can't quantify is -- and Ron and all the senior management, we have a -- very much a different culture inside Acadia. And we try to have a lot of fun, and we try to work hard, and we try to hit our expectations, and we happen to be in markets where we can do that. So -- and the length of stay, it may go down for us. But so far, we don't see that and we haven't really seen it in the past. When acute patient days -- length of stay is 9.5 days, and if you go back to the industry studies, this has been since the mid-'90s. Average length of stay for adults has been in the 9 to 10 days. And we are right in the middle of that for the second quarter. So -- and it could be just the composition of our programs and our beds and our markets. And -- but more importantly, my hats off to our operations team. Ron and that group are unbelievable.
嗯,Ana,是的,我們這一季非常出色。第二季非常出色。但你也可以看看年初至今的數字,也非常出色。我們——很明顯地,我認為我們的團隊比其他人、其他公司更好。我當然這麼認為。我們也一直這樣鼓舞士氣。我認為有一個你無法量化的因素是——Ron以及所有高階管理層,我們在Acadia內部有一種非常不同的文化。我們努力讓工作很有趣,也努力工作,並努力達成我們的預期,而我們剛好在能做到這些的市場中營運。所以——至於住院天數,它對我們可能會下降。但到目前為止,我們沒有看到,而且過去也沒有真正看到。當急性病患日——住院天數為9.5天時,如果你回頭看產業研究,這種情況自90年代中期以來一直如此。成人平均住院天數一直在9到10天之間。而我們第二季正好在這個區間的中間。所以——也可能只是我們的方案組合、床位配置與市場組合所致。而且——但更重要的是,我要向我們的營運團隊致敬。Ron和那個團隊非常了不起。
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
Helpful. Joey, just a follow-up on that, if you tie this to policy. This morning, the Senate didn't get their vote through. On the commercial side, is the likelihood now that essential benefits don't get repealed not just -- is it helpful, not just for Medicaid, but because there's an interface with mental health parities but we were hearing that it will actually help you, or at least not hurt you, on the commercial side? And then if you can talk about what CMS is proposing around behavioral health and value-based care and how that even ties to Medicare Advantage where plans are, as we're hearing, pushing more to do just consult in the long-term care setting and not have for more outpatient and not admit patients?
很有幫助。Joey,就此再追問一下,如果把這和政策連在一起。今天早上,參議院沒有讓投票通過。在商業保險端,現在基本福利(essential benefits)不被廢除的可能性,是否不只是——對Medicaid有幫助,而是因為它與心理健康同等性(mental health parity)有交互影響,我們聽到的說法是它其實會幫助你們,或至少不會在商業端傷害你們?另外,你能否談談CMS在行為健康與價值導向照護方面的提案,以及這如何與Medicare Advantage連結——因為我們聽說,計畫方正更傾向只在長期照護場域做諮詢,而不是做更多門診,也不讓病患住院?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
That's a lot in that question, Ana. First is we are glad the bill was defeated. I have not been a fan of John McCain but I'm going to send him a get-well card. So as I have kind of said all along, I think nothing was going to happen this year and it appears that nothing is going to happen. And that this will come back up next year, I think. But we're positioned well. And at the end of the day, are you providing a service for a patient that needs it? Absolutely. And can you a get reasonable reimbursement for that? Then you can make a business model. As far as the value-based, we're -- our association, our company, we are responding to the CMS on this issue and we'll just have to wait and see. That's -- the discussions are just beginning now on that issue. So -- and our team is prepared, and so is our association is very much prepared for discussions on this issue.
Ana,這個問題涵蓋很多。首先,我們很高興該法案被否決。我一向不是John McCain的粉絲,但我會寄一張祝他早日康復的卡片。所以正如我一直以來所說,我認為今年不會有任何事情發生,而看起來確實也不會發生。我想明年會再被提出。但我們的布局很好。而歸根結底,你是否在為有需要的病患提供服務?當然。而你是否能為此取得合理的給付(reimbursement)?那麼你就能建立一個商業模式。至於價值導向,我們——我們的協會、我們公司,正在就此議題回應CMS,我們只能拭目以待。這——相關討論才剛開始。所以——我們的團隊已準備好,我們的協會也非常準備好就此議題展開討論。
Operator
Operator
And have a follow-up question from Brian Tanquilut with Jefferies.
接著有一個追問,來自Jefferies的Brian Tanquilut。
Brian Gil Tanquilut - Equity Analyst
Brian Gil Tanquilut - Equity Analyst
Joey or Brent, just as we think about the cadence for the back end -- where guidance is and how you're thinking about the distribution between the next 2 quarters, without giving quarterly guidance, are there any things you would call out, other than startup costs for the hospitals being spread out evenly or pro rata between the 2 quarters? Anything that we should be thinking about?
Joey或Brent,當我們思考下半年後段的節奏——指引(guidance)所在的位置,以及你們如何看待接下來兩季之間的分布,在不提供季度指引的前提下,有沒有任何你們會特別指出的事項,除了新開院的啟動成本在兩季之間平均或按比例分攤之外?還有什麼是我們應該納入考量的嗎?
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
No, Brian. I think you should just, again, we tightened the reins just to reflect that we're halfway through the year. And I think you take the balance and split it in half, and you're going to be pretty close for the third and fourth quarter.
沒有,Brian。我認為你只要——再說一次,我們收緊了些許預期,只是反映我們已經過完上半年。我想你把剩餘的部分對半分,你對第三季和第四季的估計就會相當接近。
Operator
Operator
It appears there are no further questions at this time. I'd like to turn the conference back to Mr. Jacobs for any additional or closing remarks.
看起來目前沒有其他問題。我想把電話會議交回給Jacobs先生,請他做任何補充或結語。
Joey A. Jacobs - Chairman and CEO
Joey A. Jacobs - Chairman and CEO
Just thanks for tuning in and listening to the Acadia story. I just got back from Virginia on a new facility we got there and had a great visit. And we'll look forward to talking to you at the end of the third quarter.
感謝各位收聽並關注Acadia的故事。我剛從維吉尼亞回來,我們在那裡有一個新設施,我此行拜訪得很愉快。我們期待在第三季結束時再與各位交流。
Operator
Operator
And with that, that does conclude today's conference. We thank you for your participation.
那麼,今天的電話會議就到此結束。感謝各位的參與。